Conditions: Chronic Myeloid Leukemia Blast Crisis
Keywords: Myeloid blast phase Chronic Myeloid Leukemia (CML)
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 124
Healthy volunteers: no

Brief summary:
The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are currently in the myeloid blast phase of chronic myeloid leukemia (CML) and who are either resistant to or intolerant of imatinib mesylate. Another purpose of the study is to see what side effects this drug may have on subjects.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.

Protocol document: